SARS‐CoV‐2‐specific IgG1/IgG3 but not IgM in children with Pediatric Inflammatory Multi‐System Syndrome

Accepted/In Press date: 10 March 2021

e-pub ahead of print date: 16 March 2021

Published date: July 2021

Additional Information: Funding Information: We would like to thank the University of Birmingham Clinical Immunology Service for their invaluable support in sample collection and processing. We would like to acknowledge the support of the Birmingham Women's and Children's Hospital NHS Foundation Trust staff and patients, including Dr Fiona Reynolds, Dr Jim Gray, Dr Mitul Patel, Dr Phillip Hurley, Dr Tristan Ramcharan, Dr Habib Ali, Dr Sakeena Samar, Dr Penny Davis, Dr Kathryn Harrison, Dr William Coles, Dr Pam Dawson, Dr Sean Monaghan, Dr Deevena Chinthala, Dr Heather Duncan, Dr Nick Richens, and Dr Sanket Sontakke. We thank Jason McLellan for the expression plasmid for the SARS‐CoV‐2 glycoprotein. We are grateful to Dr Galit Alter, Harvard University, for helpful comments. We thank The Binding Site for technical assistance. We also gratefully acknowledge the University of Birmingham Protein Expression Facility for use of mammalian expression equipment. This paper presents independent research supported by the National Institute for Health Research (NIHR) Birmingham Biomedical Research Centre at the University Hospitals Birmingham NHS Foundation Trust and the University of Birmingham. The views expressed are those of the authors(s) and not necessarily those of the NHS, the NIHR, or the Department of Health. Funding Information: MTD and MG have a commercial relationship with Abingdon Health. The rest of the authors declared no conflict of interest. AFC is grateful for funding from The Medical Research Council (MC_PC_17183), the Global Challenges Research Fund (GCRF), and The Institute for Global Innovation (IGI, Project 3107) of The University of Birmingham. This study was supported by the UK National Institute for Health Research, Birmingham Biomedical Research Centres Funding scheme. Dr Barnaby Scholefield is funded by the NIHR Clinician Scientist fellowship program. The work in Prof. Max Crispin's laboratory was funded by the International AIDS Vaccine Initiative, Bill and Melinda Gates Foundation through the Collaboration for AIDS Vaccine Discovery (OPP1084519 and OPP1115782), the Scripps Consortium for HIV Vaccine Development (CHAVD) (AI144462), and the University of Southampton Coronavirus Response Fund which has over 1000 donors from around the world. Funding Information: We would like to thank the University of Birmingham Clinical Immunology Service for their invaluable support in sample collection and processing. We would like to acknowledge the support of the Birmingham Women's and Children's Hospital NHS Foundation Trust staff and patients, including Dr Fiona Reynolds, Dr Jim Gray, Dr Mitul Patel, Dr Phillip Hurley, Dr Tristan Ramcharan, Dr Habib Ali, Dr Sakeena Samar, Dr Penny Davis, Dr Kathryn Harrison, Dr William Coles, Dr Pam Dawson, Dr Sean Monaghan, Dr Deevena Chinthala, Dr Heather Duncan, Dr Nick Richens, and Dr Sanket Sontakke. We thank Jason McLellan for the expression plasmid for the SARS-CoV-2 glycoprotein. We are grateful to Dr Galit Alter, Harvard University, for helpful comments. We thank The Binding Site for technical assistance. We also gratefully acknowledge the University of Birmingham Protein Expression Facility for use of mammalian expression equipment. This paper presents independent research supported by the National Institute for Health Research (NIHR) Birmingham Biomedical Research Centre at the University Hospitals Birmingham NHS Foundation Trust and the University of Birmingham. The views expressed are those of the authors(s) and not necessarily those of the NHS, the NIHR, or the Department of Health. Copyright: Copyright 2021 Elsevier B.V., All rights reserved.

Local EPrints ID: 450090

URI: http://eprints.soton.ac.uk/id/eprint/450090

DOI: doi:10.1111/pai.13504

ISSN: 0905-6157

PURE UUID: 2b65f667-52b9-49f5-8ccf-0e1f319173e4

ORCID for Joel D. Allen: orcid.org/0000-0003-2547-968X

ORCID for Max Crispin: orcid.org/0000-0002-1072-2694

Date deposited: 09 Jul 2021 16:33

Last modified: 17 Mar 2024 06:34